Nutshell Raises C1 Capital for Allosteric Drug Design
Nutshell Therapeutics, also known as Shanghai Yudao Biotechnology, announced a C1 financing of “tens of millions of U.S. dollars” co-led by CITIC Capital and Decheng Capital, with participation from Dachen Caizhi and a Wuxi…
